ICAD said that the VeraLook detects and highlights potential polyps during CTC examinations. The newest version of VeraLook features performance improvements including a greater than 5% increase in the sensitivity of potential polyp detection, and a 20% reduction in false positives.

According to the company, extensive testing with radiologists has demonstrated that the use of VeraLook improved reader sensitivity to all colonic polyps in a manner particularly for smaller, more easily missed polyps and pre-cancerous polyps which can develop into malignancies over time.

VeraLook has also demonstrated high sensitivity in detecting polyps, while generating a low number of clinically acceptable false positive marks on CTC images. Reader and standalone testing was conducted using exams containing various types of polyps including sessile, flat and pedunculated, and on patients prepped using different methodologies.

CTC employs advanced visualization technology to produce three-dimensional images that permit a thorough and minimally invasive evaluation of the entire colorectal structure and is an accurate alternative to colonoscopy to detect polyps, the company said.

Patients undergoing a CTC exam are able to return to their normal activities immediately following the examination, as the process requires no sedation.

VeraLook has been available in Europe since June 2009 under its initial CE Mark, whereas it is pending FDA clearance in the US.

Ken Ferry, president and CEO of iCAD, said: “VeraLook is already being sold commercially in Europe and Canada, and is an important tool in helping radiologists find colon cancers earlier and with greater confidence.

“Virtual colonoscopy with CAD is a breakthrough technology that can make this potentially life-saving test accessible to a greater number of people.”